jan 1, 2015 - Talimogene Laherparepvec
Description:
FDA approves talimogene laherparepvec (T-VEC) for the treatment of some patients with metastatic melanoma that cannot be surgically removed. T-VEC, the first oncolytic virus approved for clinical use, works by infecting and killing tumor cells and stimulating an immune response against cancer cells throughout the body.Added to timeline:
Date:
jan 1, 2015
Now
~ 11 years ago